


Product Name : Etoricoxib
Cat. No. : PC-20873
CAS No. : 202409-33-4
Molecular Formula : C₁₈H₁₅ClN₂O₂S
Molecular Weight : 358.84
Target : Cyclooxygenase (COX)
Solubility : 10 mM in DMSO



CAS: 202409-33-4

Biological Activity

Etoricoxib (MK-0663) is a potent, selective and orally active inhibitor of COX-2 with IC₅₀ of 1.1 μM for COX-2 (LPS-induced prostaglandin E₂ synthesis), shows no activity against COX-1.

Etoricoxib does not inhibit platelet or human recombinant COX-1 under most assay conditions (IC₅₀>100 μM).

Etoricoxib is a potent inhibitor in models of carrageenan-induced paw edema (ID₅₀) 0.64 mg/kg, carrageenan-induced paw hyperalgesia (ID₅₀)=0.34 mg/kg, LPS-induced pyresis (ID₅₀) = 0.88 mg/kg), and adjuvant-induced arthritis (ID₅₀)=0.6 mg/kg/day) in rats.

Etoricoxib reversed LPS-induced pyresis by 81% within 2 h of administration at a dose of 3 mg/kg and showed no effect in a fecal ⁵¹Cr excretion model of gastropathy at 100 mg/kg/day for 5 days.

References

Riendeau D, et al. J Pharmacol Exp Ther. 2001 Feb;296(2):558-66.

Chauret N, et al. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1059-62.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com